2-[2-[[2-[[2-[[2-[[2-[(2-Ethylcyclopropyl)methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]ethyl hydrogen sulfate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 英文名称: 2-[2-[[2-[[2-[[2-[[2-[(2-Ethylcyclopropyl)methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]ethyl hydrogen sulfate
• 英文别名: 2-[2-[[2-[[2-[[2-[[2-[(2-ethylcyclopropyl)methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]methyl]cyclopropyl]ethyl hydrogen sulfate
• 化学式: C₂₇H₄₄O₄S
• 分子量: 464.7
• InChiKey: CTXYDOZKDQHFQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  32
• 可旋转键数：
  15
• 环数：
  6.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PKC activators and combinations thereof
  申请人：Cognitive Research Enterprises, Inc.

  公开号：US10821079B2

  公开（公告）日：2020-11-03

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。该公开进一步涉及这些组合物的组成、试剂盒、用途和方法。
• PKC ACTIVATORS AND COMBINATIONS THEREOF
  申请人：BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE

  公开号：US20140315990A1

  公开（公告）日：2014-10-23

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。本公开进一步涉及其组成物、套件、用途和方法。
• Dosing regimens of PKC activators
  申请人：COGNITIVE RESEARCH ENTERPRISES, INC.

  公开号：US11173140B2

  公开（公告）日：2021-11-16

  Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.

  公开了用于上调蛋白激酶 C (PKC) 同时减少后续下调的给药方案和方法，包括连续三周每周给药一次 PKC 激活剂，然后连续三周停止给药或给药。还描述了根据所公开的方案改善或提高认知能力、预防或治疗认知障碍、预防或治疗神经退行性疾病或病症和/或预防或治疗与神经元或突触丧失相关的疾病或病症的方法。
• STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION
  申请人：Blanchette Rockefeller Neurosciences Institute

  公开号：US20140235496A1

  公开（公告）日：2014-08-21

  The present disclosure is directed to methods of diagnosing a neurodegenerative condition, such as Alzheimer's disease, comprising contacting a cell sample from a subject with at least one stimulus, such as a protein and/or polysaccharide mixture, a protein kinase C activator, an Aβ oligomer, an agent, and combinations thereof; and detecting the expression of at least one gene in the cell sample. Methods may further comprise comparing the expression of the at least one gene in the cell sample to the expression of the same at least one gene in control cells; and determining whether the subject has the neurodegenerative condition (e.g., Alzheimer's disease), wherein a change in the expression of the at least one gene in the cell sample compared to the expression of the same at least one gene in the control cells indicates the subject has the neurodegenerative condition (e.g., Alzheimer's disease).
• TREATMENT OF NEURODEGENERATIVE CONDITIONS USING PKC ACTIVATORS AFTER DETERMINING THE PRESENCE OF THE APOE4 ALLELE
  申请人：ALKON Daniel L.

  公开号：US20180217163A1

  公开（公告）日：2018-08-02

  The present disclosure provides for methods of treating a neurodegenerative condition, as well as methods for assessing the risk of developing a neurodegenerative condition, and assessing treatment efficacy in subjects who are carriers of the ApoE4 allele. Also disclosed is a method for diagnosing a neurodegenerative disorder.